Feds close probe into Medtronic's marketing of its Infuse bone graft product

The U.S. Department of Justice spent four years looking into whether the Fridley-based manufacturer encouraged doctors to use the product in ways not described on the FDA-approved label. Medtronic denies any wrongdoing, but still faces civil lawsuits and agreed to pay $85 million in March to settle a federal securities lawsuit.